302952-79-0 Usage
Uses
Used in Oncology:
AURORA 15361 is used as an adjunct to chemotherapy and radiation therapy for enhancing their effectiveness in cancer treatment. It serves as a PARP inhibitor, preventing the repair of DNA damage in cancer cells, thereby increasing the susceptibility of these cells to therapeutic agents and leading to improved patient outcomes.
Used in Pharmaceutical Research:
In the research industry, AURORA 15361 is utilized for studying the role of PARP enzymes in DNA repair and the development of cancer. It aids in understanding the mechanisms of action and potential synergies with other therapeutic agents, contributing to the advancement of cancer treatment strategies.
Used in Drug Development:
AURORA 15361 is employed in the development of new drugs targeting the PARP enzyme, with the aim of creating novel therapeutic options for cancer patients. Its role in inhibiting DNA repair makes it a valuable component in the creation of targeted cancer therapies.
Used in the Treatment of Other Diseases:
Beyond oncology, AURORA 15361 is studied for its potential applications in treating cardiovascular and neurodegenerative disorders. Its mechanism of action in DNA repair inhibition may offer insights into the treatment of these conditions, expanding its utility across different areas of medicine.
Check Digit Verification of cas no
The CAS Registry Mumber 302952-79-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,0,2,9,5 and 2 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 302952-79:
(8*3)+(7*0)+(6*2)+(5*9)+(4*5)+(3*2)+(2*7)+(1*9)=130
130 % 10 = 0
So 302952-79-0 is a valid CAS Registry Number.
InChI:InChI=1/C17H11F3O5/c1-23-10-3-5-11(6-4-10)24-15-14(22)12-7-2-9(21)8-13(12)25-16(15)17(18,19)20/h2-8,21H,1H3
302952-79-0Relevant academic research and scientific papers
CHROMENONE DERIVATIVES FOR TREATMENT OF CANCER
-
, (2010/12/18)
4-Chromenone derivatives of the formula I herein that inhibit the ubiquitin-mediated degradation of p27, are useful for the treatment of cancer.
